
|Articles|January 1, 2008
Oncology NEWS International
- Oncology NEWS International Vol 17 No 1
- Volume 17
- Issue 1
Sunesis and MMRC collaborate to study SNS-032 in myeloma
Sunesis and MMRC collaborate to study SNS-032 in myeloma
Advertisement
SOUTH SAN FRANCISCO, California-Sunesis Pharmaceuticals, Inc. and the Multiple Myeloma Research Consortium (MMRC) have entered into a collaboration to evaluate Sunesis' SNS-032 for the treatment of multiple myeloma. SNS-032 is a potent, selective inhibitor of cyclin-dependent kinases (CDKs) 2, 7, and 9 that inhibits both cell cycle progression and transcription.
Articles in this issue
over 18 years ago
New tobacco product alert: Camel Snus is on the looseover 18 years ago
Blueberry punch not quite a 'knock out' blowover 18 years ago
Texas voters listen to Lanceover 18 years ago
Cellectar opens manufacturing facility for radiolabeled CLR1404over 18 years ago
High cost of breast MRI screening appears to be justifiedover 18 years ago
Broccoli Sprouts Extract Might Lower Bladder Cancer Riskover 18 years ago
Xeloda/Ixempra Effective in Resistant Triple-Negative Caover 18 years ago
Statins during RT may lower risk of prostate ca relapseNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
2
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
3
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
4
Achieving a “Functional Cure” With Multiple Myeloma Therapy
5


















































